ACE and renal cell adenocarcinoma: In analysis stratified by intensity of medication use, high-intensity (top tertile) use of ACE-inhibitors (392 DDD/year; HR 0.54, 95% CI 0.45–66) and ARBs (786.1 DDD/year; HR 0.66, 95% CI 0.50–0.87) was associated with decreased risk of RCC death in both age-adjusted and multivariable adjusted analysis (Table 5).